Inter- and intra-individual variability in the levels of plasma homovanillic acid in schizophrenic patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 3, 2007, Pages 713-719

  Zumárraga, Mercedes ^a   Dávila, Ricardo ^a   González Torres, Miguel Angel ^b   Anguiano, Juan B ^b   Zabalo, María José ^c   Basterreche, Nieves ^a   Arrúe, Aurora ^a   Zamalloa, María Isabel ^a   Guimón, José ^d  

^a Hospital Psiquiatrico de Zamudio   (Spain)

^b HOSPITAL DE BASURTO   (Spain)

^c AITA   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Homovanillic acid; Plasma; Schizophrenia; Variability

Indexed keywords

ANXIOLYTIC AGENT; BIPERIDEN; CLORAZEPATE; CLOTIAPINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; HOMOVANILLIC ACID; LEVOMEPROMAZINE; LORAZEPAM; NEUROLEPTIC AGENT; PERICIAZINE; SULPIRIDE; THIORIDAZINE;

ACUTE DRUG ADMINISTRATION; ADULT; AGED; ARTICLE; BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; CORRELATION ANALYSIS; DOPAMINERGIC ACTIVITY; DRUG EFFECT; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; REPRODUCIBILITY; SCHIZOPHRENIA;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; FEMALE; HOMOVANILLIC ACID; HUMANS; INDIVIDUALITY; MALE; SCHIZOPHRENIA; TIME FACTORS;

EID: 33947542070     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.01.005     Document Type: Article

References (49)

1. Amin F., Hashmi A., Stroe A.E., Adebogun O., Densmore D., and Knott P.J. Reproducibility of plasma catecholamine metabolites in normal subjects. Biol Psychiatry 43 (1998) 233-235
2. Andía I., Zumárraga M., Zabalo M.J., Bulbena A., and Dávila R. Differential effect of haloperidol and clozapine on plasma homovanillic acid in elderly schizophrenic patients with or without tardive dyskinesia. Biol Psychiatry 43 (1998) 20-23
3. Bacopoulos N.G., Hattox S.E., and Roth R.H. 3,4-Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: possible indicators of central dopaminergic activity. Eur J Pharmacol 56 (1979) 225-236
4. Baker N.L., Adler L.E., Waldo M., Gerhardt C.D., Cox B., Berry S., et al. Reproducibility of the measurement of plasma noradrenergic and dopaminergic metabolites in normal subjects. Psychiatry Res 23 (1988) 119-130
5. Bland J.M., and Altman D.G. Statistics notes: measurement error and correlation coefficients. BMJ 313 (1996) 41-42
6. Bland J.M., and Altman D.G. Statistics notes: measurement error proportional to the mean. BMJ 313 (1996) 106
7. Bowers M.B., Swigar M.E., Jatlow P.I., and Hoffman F.J. Plasma catecholamine metabolites and treatment response at neuroleptic steady state. Biol Psychiatry 25 (1989) 734-738
8. Brown A.S., Gewirtz G., Harkavy-Friedman J., Cooper T., Brébion G., Amador X.F., et al. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol. Neuropsychopharmacology 17 (1997) 317-325
9. Chang W.H., Yeh E.K., Hu W.H., Tseng Y.T., Chung M.C., and Chang H.F. Acute and chronic effects of haloperidol on plasma and brain homovanillic acid in the rat. Biol Psychiatry 21 (1986) 374-381
10. Chang W.H., Chen T.Y., Lin S.K., Lung F.W., Lin W.L., Hu W.H., et al. Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept. Biol Psychiatry 27 (1990) 510-518
11. Curtin F., Walker J.P., and Schulz P. Day to day intraindividual reliability and interindividual differences in monoamines excretion. J Affect Disord 38 (1996) 173-178
12. Davidson M., Lolonczy M.F., Mohs R.C., Lesser J.C., Powchik P., Freed L.B., et al. Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients. Neuropsychopharmacology 1 (1987) 17-23
13. Davidson M., Kahn R.S., Knott P., Kaminsky R., Cooper M., DuMont K., et al. Effects of neuroleptic treatment on symptoms on schizophrenia and plasma homovanillic acid concentrations. Arch Gen Psychiatry 48 (1991) 910-913
14. Davidson M., Kahn R.S., Powchik P., Warne P., Losonezy M.F., Kaminski R., et al. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch Gen Psychiatry 48 (1991) 73-76
15. Dávila R., Manero E., Zumárraga M., Andía I., Schweitzer J.W., and Friedhoff A.J. Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatry 45 (1988) 564-566
16. Dávila R., Zumárraga M., Andía I., and Friedhoff A.J. Persistence of cyclicity of the plasma dopamine metabolite, homovanillic acid, in neuroleptic treated schizophrenic patients. Life Sci 44 (1989) 1117-1121
17. Dávila R., Zumárraga M., Andía I., Almoguera-Abad A., and Friedhoff A.J. Early increase of plasma HVA during neuroleptic treatment: a tool for outcome prediction and for subtyping of schizophrenia. In: Friedhoff A.J., and Amin F. (Eds). Plasma Homovanollic Acid in Schizophrenia: Implications for Presynaptic Dopamine Dysfunction (1996), American Psychiatric Press Inc. 89-102
18. Dávila R, Zumárraga M, Basterreche N, Arrúe A, Anguiano JB. Changes of plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms. Psychiatry Res in press, Ref MS #6076.
19. Duncan E., Wolkin A., Angrist B., Sanfilipo M., Wieland S., Cooper T.B., et al. Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics. Biol Psychiatry 34 (1993) 523-528
20. Fraser C.G., and Harris K.H. Generation and application of data on biological variation in clinical chemistry [Review]. Crit Rev Clin Lab Sci 27 (1989) 409-437
21. Galinowski A., Castelnau C., Spreux-Varoquaux O., Bourdel M.C., Olie J.P., Loo H., et al. Evolution of plasma homovanillic acid (HVA) levels during treatment in schizo-affective disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 24 (2000) 1319-1328
22. Green A.I., Alam M.Y., Boshes R.A., Waternaux C., Pappalardo K.M., Fitzgibbon M.E., et al. Haloperidol response and plasma catecholamines and their metabolites. Schizophr Res 10 (1993) 33-37
23. Harris E.K. Statistical aspects of reference values in clinical pathology [Review]. Prog Clin Pathol 8 (1981) 45-66
24. Kaminski R., Powchick P., Warne P.A., Goldstein M., McQueeney R.T., and Davidson M. Measurement of plasma homovanillic acid concentrations in schizophrenic patients. Prog Neuro-Psychopharmacol Biol Psychiatry 14 (1990) 271-287
25. Kelley M.E., Yao F.K., and van Kammen D.P. Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia. Neuropsychopharmacology 20 (1999) 603-611
26. Kendler K.S., and Davis K.L. Acute and chronic effects of neuroleptic drugs on plasma and brain homovanillic acid in the rat. Psychiatry Res 13 (1984) 51-58
27. Kendler K.S., Heninger G.R., and Roth R.H. Brain contribution to the haloperidol-induced increase in plasma homovanillic acid. Eur J Pharmacol 71 (1981) 321-326
28. Kendler K.S., Mohs R.C., and Davis K.L. The effect of diet and physical activity on plasma homovanillic acid in normal human subjects. Psychiatry Res 8 215 (1983) 23
29. Konicki P.E., Owen R.R., Litman R.E., and Pickar D. The acute effect of central-and peripheral-acting dopamine antagonist on plasma HVA in schizophrenic patients. Life Sci 48 (1991) 1411-1416
30. Koreen A.R., Lieberman J., Alvir J., Mayerhoff D., Loebel A., Chakos M., et al. Plasma homovanillic acid levels in first episode schizophrenia. Arch Gen Psychiatry 51 (1994) 132-138
31. Labarca R., Thomas J.W., Koulu M., Kim Y.S., Janowsky A., Wilkinson L., et al. A central 6-hydroxydopamine lesion prevents flufenazine-induced increase in plasma homovanillic acid. Brain Res Bull 20 (1988) 567-571
32. Lachman H.M., Papolos D.F., Saito T., Yu Y.-M., Szumlanski C.L., and Weinshilboum M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6 (1996) 243-250
33. Mazure C.M., and Bowers M.B. Pretreatment plasma HVA predicts neuroleptic response in manic psychosis. J Affect Disord 48 (1989) 83-86
34. Mazure C.M., Nelson J.C., Jatlow P.I., and Bowers M.B. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis. Biol Psychiatry 30 (1991) 475-482
35. Mignot E., Garcia A., Laude D., Elghozi J.L., Guicheney P., Gilbert J.C., et al. Value of plasma HVA level in human: influence of renal function, food intake and psychiatric state. Biog Amines 5 (1988) 169-176
36. Pickar D., Labarca R., Linnoila M., Roy A., Hommer D., Everett D., et al. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 225 (1984) 954-956
37. Pickar D., Labarca R., Doran A.R., Wolkowitz O.M., Roy A., Breier A., et al. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry 43 (1986) 669-676
38. Reed A.H., Henry R.J., and Mason W.B. Influence of statistical method used on the resulting estimate of normal range [Review]. Clin Chem 17 (1971) 275-284
39. Reeves S., Bench C., and Howard R. Ageing and the nigrostriatal dopaminergic system [Review]. Int J Geriatr Psychiatry 17 (2002) 359-370
40. Sabol S.Z., Hu S., and Hamer D. A functional polymorphism in the monoamine A gene promoter. Hum Genet 103 (1998) 273-279
41. Sharma R., Javaid J.I., Janicak P., Faull K., Comaty J., and David J.M. Plasma and CSF HVA before and after pharmacological treatment. Psychiatry Res 28 (1989) 97-104
42. Sumiyoshi T., Saitoh O., Yotsutsuji T., Itoh H., Kurokawa K., and Kurachi M. Differential effects of mental stress on plasma homovanillic acid in schizophrenia and normal controls. Neuropsychopharmacology 20 (1999) 365-369
43. Suzuki E., Kanba S., Niyuba M., Adachi S., Sekiya U., Shintani F., et al. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients. Biol Psychiatry 36 (1994) 654-661
44. Walker E.F., Bonsall R., and Walder D.J. Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. Neuropsychiatry Neuropsychol Behav Neurol 15 (2002) 10-17
45. Williams P.D., Puddey I.B., Beilin L.J., and Vandongen R. Genetic influences on plasma catecholamines in human twins. J Clin Endocrinol Metab 77 (1993) 794-799
46. Yoshimura R., Ueda N., Shinkai K., and Nakamura J. Plasma levels of homovanillic acid in the response to risperidone in first episode untreated acute schizophrenia. Int Clin Psychopharmacol 18 (2003) 107-111
47. Zumárraga M., Andía I., Bárcena B., Zamalloa M.I., and Dávila R. Liquid chromatographic method for the determination of homovanillic acid in plasma with electrochemical detection. Clin Chem 33 (1987) 72-75
48. Zumárraga M., Andía I., Bárcena B., González-Torres M.A., and Dávila R. Morning variations of plasma homovanillic acid in untreated schizophrenic patients. J Psychiatr Res 27 (1993) 11-16
49. Zumárraga M., Andía I., Dávila R., and Zamalloa M.I. Homovanillic acid in plasma determined by HPLC with direct injection of plasma filtrates [Letter to the editor]. Clin Chem 40 (1994) 2119-2120